Exome Asset Management LLC Makes New $982,000 Investment in MBX Biosciences, Inc. $MBX

Key Points

• Exome Asset Management LLC acquired 133,113 shares in MBX Biosciences, valued at approximately $982,000, representing 0.40% of the company's stock.
• MBX Biosciences has recently seen increased investments from various institutional investors, with one hedge fund investing over $8 million in the first quarter.
• Wall Street analysts have a consensus rating of "Buy" for MBX shares, with a target price averaging around $37.63 according to recent coverage from firms like Mizuho and Oppenheimer.

Exome Asset Management LLC acquired a new position in MBX Biosciences, Inc. (NYSE:MBX - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 133,113 shares of the company's stock, valued at approximately $982,000. Exome Asset Management LLC owned 0.40% of MBX Biosciences as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. BNP Paribas Financial Markets acquired a new stake in shares of MBX Biosciences in the 4th quarter worth about $27,000. New York State Common Retirement Fund acquired a new position in MBX Biosciences during the 1st quarter valued at about $32,000. Deutsche Bank AG increased its stake in MBX Biosciences by 102.0% during the 1st quarter. Deutsche Bank AG now owns 8,762 shares of the company's stock valued at $65,000 after buying an additional 4,424 shares during the period. Wealthedge Investment Advisors LLC acquired a new position in MBX Biosciences during the 1st quarter valued at about $88,000. Finally, Nuveen LLC acquired a new position in MBX Biosciences during the 1st quarter valued at about $107,000.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Mizuho assumed coverage on shares of MBX Biosciences in a research note on Tuesday, August 5th. They set an "outperform" rating and a $38.00 target price on the stock. Oppenheimer assumed coverage on shares of MBX Biosciences in a research note on Wednesday, July 16th. They set an "outperform" rating and a $38.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, MBX Biosciences currently has an average rating of "Buy" and a consensus target price of $37.63.

MBX Biosciences Price Performance

Shares of MBX traded up $0.90 during mid-day trading on Friday, hitting $10.83. The company's stock had a trading volume of 684,563 shares, compared to its average volume of 329,784. The firm has a 50-day moving average price of $13.09 and a 200 day moving average price of $10.99. The stock has a market capitalization of $363.82 million and a price-to-earnings ratio of -2.39. MBX Biosciences, Inc. has a fifty-two week low of $4.81 and a fifty-two week high of $27.50.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.